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Abstract 26 
Objectives: This study investigated associations between incident hyperkalemia during acute heart 27 
failure (HF) hospitalizations and changes in renin–angiotensin–aldosterone-system inhibitors (RAASi). 28 
Background: Hyperkalemia is a potential complication of RAASi. For patients with HF, fear of 29 
hyperkalemia may lead to failure to deliver guideline-recommended doses of RAASi.  30 
Methods: Serum potassium concentrations were measured daily from baseline (<24h of admission) 31 
until discharge or day 7 in 1,589 patients enrolled in the PROTECT trial. Incident hyperkalemia was 32 
defined as at least one episode of potassium >5.0 mEq/L. The primary outcome was all-cause 33 
mortality at 180 days.  34 
Results: Overall, serum potassium concentrations increased from 4.3±0.6 mEq/L at baseline to 35 
4.5±0.6 mEq/L at discharge/day 7 (p<0.001). Patients developing incident hyperkalemia (n=564; 35%) 36 
were more often on mineralocorticoid antagonists (MRAs) prior to hospitalization and were more 37 
likely to have them down-titrated during hospitalization, independent of confounders. Incident 38 
hyperkalemia was not associated with adverse outcomes. Yet, down-titration of MRAs during 39 
hospitalization was independently associated with 180-day mortality (HR 1.73; 95%CI 1.15–2.60), 40 
regardless of incident hyperkalemia (Pinteraction>0.1). Patients with incident hyperkalemia, who were 41 
discharged on the same or an increased dose of MRAs (HR 0.52; 95%CI 0.32–0.85) or ACEi/ARB (HR 42 
0.47; 95%CI 0.29–0.77) had a lower 180-day mortality.  43 
Conclusions: Incident hyperkalemia is common in patients hospitalized for acute HF and is not 44 
associated with adverse outcomes. Incident hyperkalemia is associated with down-titration of MRAs, 45 
but patients who maintained or increased their dose of MRAs and/or ACEi/ARB during acute HF 46 
hospitalization had better 180-day survival.  47 
 48 
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List of abbreviations 51 
ACEi – Angiotensin-Converting Enzyme-Inhibitors 52 
ARB – Angiotensin Receptor Blockers 53 
BNP – Brain Natriuretic Peptide 54 
eGFR – estimated Glomerular Filtration Rate 55 
HF – Heart Failure 56 
HFpEF – Heart Failure with preserved Ejection Fraction 57 
MRAs – Mineralocorticoid Receptor Antagonist 58 
RAASi – Renin Angiotensin Aldosterone System-Inhibitors   59 
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Introduction 60 
The treatment of heart failure requires the use of a variety of agents that may cause both hypo and 61 
hyperkalemia and both may be associated with a higher mortality in some clinical settings.(1–5)  62 
Hospitalizations for worsening heart failure is often associated with intensification of diuretic 63 
therapy that may cause hypokalemia, and initiation or adjustment of the dose of life-saving therapies 64 
including renin-angiotensin-aldosterone system inhibitors (RAASi), which may cause hyperkalemia.(6) 65 
Accordingly, guidelines recommend close monitoring of serum potassium during hospitalizations for 66 
HF and that RAASi, both angiotensin converting enzyme inhibitors and angiotensin receptor blockers 67 
(ACEi/ARB) and mineralocorticoid receptor antagonists (MRAs), should be avoided or down-titrated if 68 
serum potassium exceeds 5.0 mEq/L.(7–9)  69 
Higher serum potassium concentrations are associated with less successful up-titration of 70 
ACEi/ARB in patients with chronic HF.(10) Similarly, among patients with chronic HF, hyperkalemia is 71 
associated with underuse of mineralocorticoid receptor antagonists (MRAs).(11, 12) However, data 72 
on the association between incident hyperkalemia and up- or down-titration of RAASi during 73 
hospitalization for acute HF are scant.  74 
Therefore, we investigated the relationship between hyperkalemia and adjustment of the 75 
dose of RAASi in patients hospitalized with acute HF and subsequent clinical outcome.  76 
 77 
Methods 78 
Study design and population 79 
Patients enrolled in the PROTECT trial (Placebo-Controlled Randomized Study of the Selective 80 
A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated 81 
Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function), 82 
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who had measurements of serum potassium on at least 5 days during their index hospital admission 83 
were included in this analysis. Differences in clinical characteristics between patients included and 84 
excluded using these criteria are shown in supplementary table 1. Detailed descriptions of the 85 
design, implementation, and results have been reported elsewhere.(13, 14) In short, patients with 86 
pre-existing HF, mild or moderate renal impairment (estimated creatinine clearance, 20–80 mL/min), 87 
increased plasma concentrations of brain natriuretic peptides, and breathlessness at rest or minimal 88 
exertion associated with symptoms and signs of volume overload requiring intravenous diuretic 89 
therapy who had a serum potassium ≥3.5 mEq/L (or 3.0-3.5 mEq/L if potassium was given 90 
intravenously), were enrolled within 24 hours of admission and randomized to Rolofylline (a selective 91 
A1 adenosine receptor antagonist) or placebo. 92 
 93 
Definitions and study endpoints 94 
Serum concentrations of potassium were classified according to clinical reference ranges, i.e. 95 
hypokalemia (<3.5 mEq/L) and hyperkalemia (>5.0 mEq/L).(15) Serum potassium concentrations 96 
were measured daily from baseline (<24 hours) until discharge or until day 7. Patients were classified 97 
as ‘Incident hypokalemia’ if they developed hypokalemia at some point (≥ 1 time) during 98 
hospitalization, but no hyperkalemia. The ‘Normal potassium’ group was defined as having a serum 99 
potassium of 3.5–5.0 mEq/L for all measurements until discharge or day 7. Patients who developed 100 
hyperkalemia during hospitalization (once or more), but never had hypokalemia, were classified as 101 
‘Incident hyperkalemia’. Patients developing both hypo- and hyperkalemia during hospitalization 102 
(n=34) were excluded for this analysis.  103 
 A change in serum potassium was defined as difference of ≥0.2 mEq/L between day 1 and 104 
discharge or day 7. Worsening renal function (WRF) was defined as a creatinine change until day 7 105 
(from baseline) ≥0.3 mg/dL in accordance with an earlier study originating from the PROTECT 106 
cohort.(16) Changes in cardiovascular treatment were stratified into four categories, i.e. treated 107 
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neither at admission or discharge, dose decreased or discontinued (down-titration), no dose change, 108 
or dose increased or initiated (up-titration). All-cause mortality at 180 days was the primary outcome 109 
for this analysis and the composite of rehospitalization for cardiovascular or renal causes or all-cause 110 
mortality through 60 days was a secondary outcome of interest.  111 
 112 
Statistical analysis 113 
For baseline characteristics, means ± standard deviations, medians (interquartile ranges), or numbers 114 
with percentages were used as appropriate. Characteristics were stratified by the various clinical 115 
ranges (incident hypokalemia, normal potassium throughout hospitalization, incident hyperkalemia) 116 
until discharge or day 7. Differences between groups were tested using the one-way analysis of 117 
variance (ANOVA), chi-square test, or Kruskal-Wallis test as appropriate. To test all variables for 118 
normality, histograms or Q-Q plots were used. If in doubt, normality was tested via the Kolmogorov-119 
Smirnov test. To achieve normal distribution for further analysis, skewed variables were log-120 
transformed.  121 
Intergroup differences related to changes in doses of ACEi/ARB and MRAs during 122 
hospitalization were depicted using stacked bar charts and tested using chi-square tests. To correct 123 
for treatment indication-bias, analyses related to the effect of ACEi/ARB and MRA up- or down-124 
titration were corrected for the probability of obtaining this specific therapy. For this correction we 125 
used inverse probability weighting (IPW) with the probability to be up-titrated for either ACEi/ARB or 126 
MRAs.(17) We performed IPW by doing logistic LASSO penalization analysis using all 69 variables 127 
averaged over 5 imputation sets for both ACEi/ARB and MRA separately. We defined successful 128 
treatment as those who were able to be up-titrated or remained constant doses of either ACEi/ARB 129 
or MRA. The derived weights were used in the subsequent survival analysis.  130 
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The association of clinical variables with incident hypo- and hyperkalemia was tested using 131 
logistic regression analyses. All variables with a univariate association <0.1 were used in multivariable 132 
models. Similar logistic regression models were used to test the predictive value of incident 133 
hyperkalemia on dose changes in cardiovascular treatment. The effect of baseline serum potassium 134 
concentrations (on a continuous scale) or the number of days hyperkalemia occurred on down-135 
titration of ACEi/ARB or MRA was tested using logistic regression models as well. In addition, we 136 
created a robust multivariable model including clinically relevant confounders. 137 
Cox proportional hazard models were used to test the effects of up- or down-titration of 138 
ACEi/ARB and MRAs on outcome, adjusting for age, sex, logarithm of estimated glomerular filtration 139 
rate (eGFR), and logarithm of total diuretic dosage of loop diuretics (oral dose/2 + IV dose until day 7 140 
or discharge) (Model 1) and for the PROTECT Risk Engine.(18) This model includes 8 variables 141 
measured at baseline; age, previous HF hospitalizations, peripheral edema, systolic blood pressure, 142 
serum albumin, creatinine, sodium, and urea concentrations. Interaction analyses were performed to 143 
investigate the interaction for outcome between changes in cardiovascular treatment during 144 
hospitalization and potassium abnormalities. The effect of incident dyskalemia on outcome was 145 
depicted using Kaplan Meier curves and tested in multivariate analysis using Cox proportional hazard 146 
models correcting for Model 1 or the PROTECT Risk Engine.(18)  147 
A two-sided p-value <0.05 was considered statistically significant. Stata SE15 (StataCorp. 148 
2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC) was used for 149 
statistical analyses. 150 
 151 
Results 152 
Baseline characteristics 153 
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Overall, serum potassium concentrations increased from 4.3±0.6 mEq/L at baseline to 4.5 ± 0.6 154 
mEq/L at discharge or day 7, p<0.001. The average potassium change during hospitalization was 0.22 155 
± 0.68 mEq/L. Incident hypokalemia occurred in 265 patients (17%) and incident hyperkalemia in 564 156 
patients (35%). Out of these, 28 patients (5%) had hyperkalemia at only one day of hospitalization. In 157 
total, 34 patients (2%) had episodes of both hypo- and hyperkalemia. Only for frequency analyses, 158 
we narrowed the definition of incident hyperkalemia to >5.5 mEq/L (moderate hyperkalemia) or >6.0 159 
mEq/L (severe hyperkalemia). Then 226 (14%) and 87 (5%) patients were classified as incident 160 
hyperkalemia, respectively.  161 
Patients with incident hyperkalemia were younger, with fewer signs of congestion, a higher 162 
heart rate, and a lower prevalence of atrial fibrillation/flutter (P<0.05 for all) but had similar renal 163 
function (eGFR) to other patient groups. However, WRF until day 7 was observed more frequently in 164 
the groups with incident dyskalemia (25% for incident hypokalemia, 17% for normokalemia, and 26% 165 
for incident hyperkalemia, p<0.001). Patients who developed incident hyperkalemia were more often 166 
on MRAs (53%) and ACEi/ARB (78%) prior to hospitalization compared to patients with incident 167 
hypokalemia or who had a ‘normal potassium’ (35% and 44% for MRAs, and 68% and 77% for 168 
ACEi/ARB, respectively) (table 1). In a multivariable analysis, patients with incident hyperkalemia 169 
were younger, more often treated with MRAs, and received lower doses of loop diuretics during 170 
hospitalization. In addition, hyperkalemic episodes were associated with lower serum sodium 171 
concentrations, a higher platelet count, and higher serum concentrations of chloride and BUN 172 
(supplementary table 2).  173 
Independent predictors of incident hypokalemia were lower serum concentrations of 174 
chloride, higher serum concentrations of bicarbonate and BNP, higher doses of loop diuretics, and 175 
not receiving MRAs at baseline (supplementary table 3).  176 
 177 
Changes in cardiovascular treatment 178 
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For patients with incident hyperkalemia, MRAs were more often down-titrated (15%) compared to 179 
patients whose potassium remained in the normal range (9%) or with incident hypokalemia (8%) 180 
(figure 1 and supplementary table 4). After correcting for confounders (i.e. age, sex, eGFR, and total 181 
doses of loop diuretics until day 7 or discharge) or correction for all variables with a univariate 182 
association with MRA down-titration (univariable P<0.1), this association remained significant (OR 183 
1.81; 95%CI 1.27–2.58, p=0.001 and OR 1.89; 95%CI 1.32–2.72, p=0.001, respectively). In sensitivity 184 
analyses using IPW, this association was not attenuated (OR 1.88; 95%CI 1.30–2.73, p=0.001). Doses 185 
of ACEi/ARB were not decreased more frequently in patients with incident hyperkalemia compared 186 
to patients with normal potassium concentrations throughout or those with incident hypokalemia 187 
(P=0.296). Patients with incident hypokalemia were less often treated with MRA or ACEi/ARB during 188 
hospitalization (figure 1). However, after multivariable adjustment this was no longer significant for 189 
either therapies class (P=0.061 and P=0.380 respectively). Difference at baseline between subgroups 190 
of treatment change for ACEi/ARB and MRA are listed in supplementary tables 5 and 6 respectively.  191 
 In univariable analysis, the number of days with hyperkalemia was not associated 192 
with ACEi/ARB down-titration (OR: 1.06 (0.89–1.27), p=0.517) (table 3). However, the number of 193 
instances that hyperkalemia occurred was associated with down-titration of MRAs (OR: 1.26 (1.09–194 
1.47), p=0.003). This association remained significant after correction for variables with a univariable 195 
association with MRA down-titration (OR: 1.23 (1.04–1.44), p=0.014) or after robust correction for 196 
various clinical confounders (OR: 1.41 (1.02–1.97), p=0.040). 197 
 When tested on a continuous scale, baseline serum potassium was not associated with 198 
ACEi/ARB down-titration (table 3). Yet, it was positively associated with MRA down-titration (OR: 199 
1.45 (1.10-1.91), p=0.008) in univariable analysis. However, this effect was no longer significant after 200 
correction for clinical confounders (OR: 1.51 (0.87-2.62), p=0.139). 201 
 202 
Incident potassium disturbances, RAAS-I therapy, and outcome 203 
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Overall, 269 (17%) patients died within 180 days and 434 patients (27%) experienced the composite 204 
secondary outcome. No association was observed between incident hypo- or hyperkalemia and 205 
either outcome or the composite outcome (supplementary figure 1), even when hyperkalemia was 206 
defined as >5.5 mEq/L. However, the number of days a patient suffered from hyperkalemia was 207 
associated with 180-day mortality, even after correction for the PROTECT Risk Engine (HR 1.14 (1.00–208 
1.30), p=0.049).  209 
Compared to constant doses, down-titration or absence of ACEi/ARB at baseline and 210 
discharge/day 7 was associated with a higher 180-day mortality on both unadjusted and adjusted 211 
analyses (table 2). Furthermore, when using IPW, the associations persisted (HR 2.56; 95%CI 1.83–212 
3.60, p<0.001, respectively). A similar pattern was observed for MRA down-titration during 213 
hospitalization. Also for MRAs, IPW did not attenuate this association (HR 1.67; 95%CI 1.11–2.49, 214 
p=0.013). Additional correction for treatment with the study drug (Rolofylline) or placebo had no 215 
impact on outcomes.  216 
 Incident hyperkalemia had no impact on the association between RAASi and a favorable 217 
outcome. Patients with incident hyperkalemia and constant doses or increasing doses of MRA had a 218 
lower mortality (HR 0.58; 95%CI 0.37–0.91) compared to patients who did not receive an MRA or 219 
who had doses reduced. Additional IPW analysis did not attenuate this beneficial effect (HR 0.52; 220 
95%CI 0.32–0.85). Similarly, patients with incident hyperkalemia and constant or increasing doses of 221 
ACEi/ARB had a lower mortality (HR 0.46; 95%CI 0.28–0.75). This association was not attenuated in 222 
an IPW analysis (HR 0.47; 95%CI 0.29–0.77). No interaction was observed between incident 223 
hyperkalemia and up-titration of ACEi/ARB or MRAs during hospitalization for either all-cause 224 
mortality at 180 days or the secondary composite outcome (Pinteraction>0.1 for all). Additionally, when 225 
tested in potassium sub-groups, patients with incident hyperkalemia and ACEi/ARB down-titration 226 
had a worse 180-day prognosis compared to patients with stable ACEi-/ARBdoses. This was not seen 227 
for MRA (supplementary table 9). 228 
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 229 
Discussion 230 
This analysis shows that patients hospitalized for acute HF often develop hyperkalemia and if they 231 
do, they are more likely to have doses of MRAs reduced or stopped. Although incident hyperkalemia 232 
was not directly associated with longer-term outcomes, incident hyperkalemia was associated with 233 
lower use of RAASi. Patients who developed hyperkalemia fared better if the doses of MRA or 234 
ACEi/ARB were held constant or increased.  235 
We are unaware of any other trial of hospital admission for HF with such a high density of 236 
measurements of serum potassium. More than half of patients in this analysis developed either 237 
hypo- or hyperkalemia during hospital admission. Hyperkalemia was most prevalent occurring in 35% 238 
of patients at least once, while 17% of patients experienced hypokalemia at least once during 239 
hospitalization. Incident serum potassium >5.5 mEq/L or >6.0 mEq/L was seen in 14% and 5% of 240 
patients, respectively. Many clinical trials of heart failure, especially involving RAASi, excluded 241 
patients with a baseline serum potassium >5.0 mEq/L which was designed to reduce the risk of 242 
developing severe hyperkalemia.(19, 20) Earlier reports from the PROTECT trial reported that 6% of 243 
acute HF patients had hyperkalemia at baseline.(21) In the Efficacy of Vasopressin Antagonism in 244 
Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, 14.6% of patients hospitalized with 245 
worsening heart failure had hyperkalemia at discharge.(22) In a recent study, exploring the effect of 246 
long-term monitoring of serum potassium after hospitalizations for acute HF, 5.6% of patients 247 
developed hyperkalemia post-discharge.(4)  248 
Patients at risk for developing hyperkalemia during hospitalization were more often treated 249 
with MRAs prior to hospitalization, in keeping with the results of the RALES Randomized Aldactone 250 
Evaluation Study) and EMPHASIS-HF trials (Eplerenone in Mild Patients Hospitalization and Survival 251 
Study in Heart Failure), which showed that patients treated with MRAs developed hyperkalemia 252 
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more often during follow up.(20, 23) Many trials of HF have shown that older patients with diabetes 253 
and renal dysfunction treated with RAASi are more likely to develop hyperkalemia.(21–24) The fact 254 
that we did not find similar associations with incident hyperkalemia suggests that changes in RAASi 255 
may be of overriding importance during hospitalization for acute HF. However, within the ‘incident 256 
hyperkalemia’ group, patients who were down-titrated with ACEi/ARB or MRAs, more frequently had 257 
a history of diabetes mellitus and showed a worse renal function compared to patients with incident 258 
hyperkalemia and stable doses or up-titration of ACEi/ARB or MRAs (supplementary tables 5 and 6). 259 
The greater incidence of hyperkalemia in younger people in our study may reflect greater efforts and 260 
success in treating them with MRA. Hypokalemia was strongly associated with not being treated with 261 
an MRA. In addition, by using a multi-day method of in-hospital monitoring, our study indicated that 262 
patients with a higher severity of hyperkalemia (defined as more days with serum potassium 263 
concentrations above 5.0 mEq/L), were more likely to be down-titrated with MRAs. 264 
In this study, a mortality rate of 17% was seen after a follow-up period of 180 days. For the 265 
combined outcome of all-cause mortality and cardiovascular or renal rehospitalization at 60 days an 266 
incidence rate of 27% was seen (supplementary table 8). Similar to previous reports, incident hypo- 267 
or hyperkalemia during hospitalization was not associated either with mortality or our secondary 268 
composite outcome.(21–23, 25) However, incident hyperkalemia was strongly associated with down-269 
titration of MRA therapy which was, in turn, associated with a worse prognosis. A previous report 270 
from the Swedish HF Registry indicated that hyperkalemia was not related to underuse of MRAs.(26) 271 
In contrast, analyses of the BIOSTAT-CHF cohort, including patients with chronic HF, indicated 272 
hyperkalemia to be associated with less successful up-titration of ACEi/ARB and underuse of 273 
MRA.(10, 12) Unfortunately, no specific data on up- or down-titration of MRA therapy was available 274 
in this chronic HF cohort. Additionally, real-world data of the SCREAM study (Stockholm CREAtinine 275 
Measurements) indicated hyperkalemia to be common after MRA initiation, yet with frequent 276 
therapy interruption as a consequence, especially among participants with chronic kidney 277 
disease.(11) 278 
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Our results indicated higher survival rates, after up-titration or constant doses of either 279 
MRAs or ACEi/ARB, are also seen in patients with incident hyperkalemia. This indicates that 280 
hyperkalemia at times of intense cardiovascular treatment might not attenuate the beneficial effects 281 
of these therapeutic agents, which is in accordance to earlier findings from a post-hoc analysis of the 282 
EMPHASIS-HF trial regarding chronic HFrEF patients.(27) This might be of additional interest, taking 283 
the novel therapeutics to lower serum potassium concentrations into account.(28, 29)  284 
 285 
Study limitations 286 
The PROTECT trial did not include patients with serum potassium concentrations below 3.0 mEq/L. 287 
Patients with serum potassium concentrations between 3.0–3.5 could only be included in case 288 
potassium was supplemented parentally. However, no data is available regarding the dose 289 
supplements. In patients with chronic HF, oral potassium supplements did not affect mortality(30) 290 
The associations highlighted in this paper need to be considered in the light of a clinical trial setting. 291 
For instance, the proportion of patients treated with the study drug (Rolofylline) was not equally 292 
distributed between potassium subgroups (p=0.039). Since an earlier study by Liu et al. indicated that 293 
the effect of Rolofylline on mortality is similar throughout the spectrum of baseline serum potassium 294 
concentrations, we do not expect this finding to be of major impact on our results.(31) Besides, 295 
treatment with Rolofylline had no impact on our multivariable outcome models. Changes in RAASi 296 
were recorded between baseline and day 7, whereas serum potassium concentrations were 297 
measured daily. We did not record why investigators changed doses of RAASi, which will have been 298 
influenced by patients’ symptoms and signs, blood pressure and renal function. Additionally, since 299 
changes in RAASi were only recorded within this specific time window, the effects of dose 300 
adjustments after day 7 might have affected outcomes. The incidence of hyperkalemia and its effect 301 
on RAASi use might be distorted, compared to clinical practice, by the close monitoring of patients 302 
and their serum potassium. In clinical practice, serum potassium will usually be measured less often, 303 
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which may mean that hyperkalemia is often missed but is more severe when it eventually is. We only 304 
included patients with five or more measurements of serum potassium which effectively excluded 305 
early deaths. Of 47 (3%) patients who died within 7 days of enrollment, 14 (30%) patients showed a 306 
serum potassium concentration >5.0mEq/L at some point during hospitalization. Serum potassium 307 
concentrations may fluctuate markedly in the acute setting and may not reflect post-discharge 308 
measurements. This could account for the dissociation between in-patient measurements of 309 
potassium and long-term outcome that we observed. Other reports suggest that hypo- and 310 
hyperkalemia are strongly related to in-patient prognosis (UK National HF Audit on ~30,000 patients).  311 
 312 
 313 
Conclusion 314 
Incident hyperkalemia is common during hospitalization for acute HF but is not associated with a 315 
worse post-discharge prognosis. However, incident hyperkalemia is associated with underuse of 316 
MRAs, which is associated with an increased risk of mortality at 180 days. Survival analyses indicate 317 
that patients still benefit from constant doses or up-titration of MRAs and/or ACEi/ARB despite 318 
incident hyperkalemia in a clinical setting. 319 
 320 
Clinical Perspectives: Even though incident hyperkalemia is common during hospitalization for acute 321 
HF, it does not result in impaired prognosis. However, it is associated with down-titration of MRAs, 322 
which is associated with worse outcomes. The authors reported patients with incident hyperkalemia, 323 
who were discharged on the same or an increased dose of MRAs and/or ACEi/ARB had a lower 180-324 
day mortality.  325 
 326 
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Translational Outlook: This study provides data for associations between incident hyperkalemia and 327 
RAASi to tailor this therapy in patients hospitalized for acute HF. These data may also support the 328 
design of trials to, for example, explore the serum potassium concentration at which RAASi doses 329 
should be reduced, should be reconsidered. The effect of treatments designed to manage 330 
hyperkalemia should be assessed not only to determine if they can increase the proportion of 331 
patients achieving target doses of RAASi but if this strategy leads to reductions in morbidity and 332 
mortality. 333 
  334 
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Figure 1. Stacked bar charts depicting changes in cardiovascular therapy between admission and 424 
discharge for ACEi/ARB (p=0.001) and MRA (p<0.001). Stratified by developing incident hypokalemia, 425 
normal potassium concentrations throughout hospitalization, and incident hyperkalemia during 426 
hospitalization, p-value for overall intergroup differences. 427 
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Table 1. Baseline characteristics, stratified by incident hypokalemia, always normal potassium, and 429 
incident hyperkalemia during hospitalization until discharge or day 7.  430 
Variables Level 
Total cohort 
(n=1589) 
Hypokalemia ≥1 
(n=265) 
No abnormalities  
(n=760) 
Hyperkalemia ≥1 
(n=564) p-value 
Demographics: 
Potassium (mEq/L)  
 
4.3 ± 0.6 3.7 ± 0.5 4.2 ± 0.4 4.7 ± 0.6 N.A. 
Age, years 
 
70.0 ± 11.4 70.5 ± 12.5 70.7 ± 11.1 68.8 ± 11.2 0.007 
Male sex 
 
1060 (66.7%) 165 (62.3%) 527 (69.3%) 368 (65.2%) 0.072 
BMI, kg/m2 
 
28.7 ± 6.1 28.6 ± 6.4 29.1 ± 6.3 28.3 ± 5.6 0.074 
eGFR, mL/min/1.73 m2 
 
48.6 ± 19.3 48.4 ± 18.8 49.1 ± 18.6 47.9 ± 20.4 0.53 
NYHA class  0.17 
 
I/II 249 (16.5%) 47 (18.8%) 122 (16.9%) 80 (15.0%) 
 
 
III 751 (49.8%) 122 (48.8%) 375 (51.9%) 254 (47.6%) 
 
 IV 507 (33.7%) 81 (34.4%) 226 (31.3 %) 200 (37.5%)  
Systolic BP, mmHg 
 
124.8 ± 17.5 125.2 ± 19.6 124.7 ± 17.3 124.7 ± 16.8 0.93 
Heart rate, b.p.m. 
 
80.6 ± 15.5 80.1 ± 16.2 79.7 ± 15.2 81.9 ± 15.6 0.034 
Signs & symptoms: 
Orthopnea 
 
1349 (85.7%) 219 (83.9%) 659 (87.6%) 471 (83.8%) 0.10 
Angina pectoris 
 
383 (24.1%) 61 (23.0%) 159 (20.9%) 163 (28.9%) 0.003 
Edema & raised JVP 
 
433 (30.3%) 92 (37.6%) 202 (29.8%) 139 (27.5%) 0.018 
Rales 
 
165 (10.4%) 30 (11.3%) 69 (9.1%) 66 (11.7%) 0.27 
History of: 
Hospitalization for HF  
previous year 
 
802 (50.5%) 138 (52.1%) 382 (50.3%) 282 (50.0%) 0.85 
Myocardial infarction 
 
794 (50.1%) 121 (45.7%) 384 (50.7%) 289 (51.3%) 0.28 
Hypertension 
 
1268 (79.8%) 201 (75.8%) 619 (81.4%) 448 (79.4%) 0.14 
Hyperlipidemia 
 
777 (48.9%) 134 (50.6%) 397 (52.2%) 246 (43.6%) 0.007 
Current smoker 
 
317 (20.0%) 50 (18.9%) 169 (22.3%) 98 (17.4%) 0.080 
COPD or asthma 
 
309 (19.5%) 51 (19.2%) 148 (19.5%) 110 (19.5%) 0.99 
Diabetes mellitus 
 
723 (45.5%) 116 (43.8%) 342 (45.0%) 265 (47.0%) 0.64 
Atrial fibrillation/flutter 
 
857 (54.2%) 143 (54.2%) 423 (55.8%) 291 (52.1%) 0.040 
Cardiovascular treatment: 
Beta-blockers 
 
1219 (76.7%) 204 (77.0%) 590 (77.6%) 425 (75.4%) 0.62 
ACEi/ARB 
 
1202 (75.6%) 181 (68.3%) 583 (76.7%) 438 (77.7%) 0.009 
MRA 
 
726 (45.7%) 93 (35.1%) 337 (44.3%) 296 (52.5%) <0.001 
22 
 
Digoxin 
 
476 (30.0%) 70 (26.4%) 236 (31.1%) 170 (30.1%) 0.36 
IV loop diuretic dose 
administered on day 1 
 
80 (40, 140) 100 (60, 180) 80 (40, 150) 80 (40, 120) <0.001 
Oral dosage loop diuretic 
administered on day 1 
 
40 (25, 60) 40 (20, 80) 40 (25, 60) 40 (25, 60) 0.32 
Treated with Rolofylline 
(study drug) 
 
1,052 (66.2%) 187 (70.6%) 480 (63.2%) 385 (68.3%) 0.039 
Laboratory: 
BNP (pg/mL) 
 
452 (258, 830) 581 (324, 981) 393 (243, 751) 461 (263, 826) <0.001 
Albumin (g/dL) 
 
3.8 ± 0.4 3.8 ± 0.5 3.9 ± 0.4 3.9 ± 0.4 0.039 
Bicarbonate (mEq/L)  
 
24.0 ± 3.8 25.3 ± 3.9 24.1 ± 3.6 23.2 ± 38 <0.001 
Chloride (mEq/L) 
 
101.1 ± 4.9 99.8 ± 5.5 101.2 ± 4.6 101.6 ± 5.0 <0.001 
Sodium (mEq/L) 
 
139.5 ± 4.1 139.8 ± 4.5 139.6 ± 3.9 139.3 ± 4.2 0.17 
Urea (BUN) (mg/dL) 
 
29 (22, 40) 29 (21, 40) 28 (22, 39) 31 (23, 42) 0.028 
Uric acid (mg/dL) 
 
9.0 ± 2.6 9.4 ± 2.8 8.9 ± 2.5 9.0 ± 2.5 0.032 
Serum glucose (mg/dL) 
 
126 (103, 163) 132 (106, 159) 126 (103, 164) 123 (99, 166) 0.46 
Hemoglobin (g/dL) 
 
12.7 ± 2.0 12.6 ± 2.0 12.7 ± 1.9 12.9 ± 2.0 0.14 
Platelets (x109/L)  
 
217 (175, 271) 205 (163, 251) 215 (173, 269) 226 (180, 284) 0.002 
White blood cells (x109/L) 
 
7.5 (6.1, 9.3) 7.3 (5.8, 9.3) 7.4 (6.0, 9.3) 7.7 (6.3, 9.2) 0.16 
Total cholesterol (mg/dL)  
 
148 ± 45 139 ± 45 146 ± 44 154 ± 46 <0.001 
Values are given as proportions, means (±SD) or medians (IQR) 431 
ACEi = Angiotensin-Converting Enzyme Inhibitors, ARB = Angiotensin Receptor Blockers, BMI = Body Mass Index, BNP = 432 
Brain Natriuretic Peptide, b.p.m. = beats per minute, BUN = Blood Urea Nitrogen, COPD = Chronic Obstructive Pulmonary 433 
Disease, eGFR = estimated Glomerular Filtration Rate, HFpEF = Heart Failure with preserved Ejection Fraction, IV= 434 
intravenous, JVP = Jugular Venous Pressure, MRA = Mineralocorticoid Receptor Antagonists, NYHA = New York Heart 435 
Association, Systolic BP = Systolic Blood Pressure. 436 
 437 
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Table 2. Cox proportional hazard regression for mortality risk at 180 days after change in 439 
cardiovascular treatment during hospitalization. 440 
Change in  
cardiovascular treatment 
Univariable Model 1
$
 PROTECT Risk Engine* 
ACEi/ARB 
No dose change (Reference) HR (CI), p  HR (CI), p HR (CI), p 
Dose increased or initiated 1.03 (0.69 – 1.52), 0.895 1.01 (0.70 – 1.48), 0.940 1.02 (0.68 – 1.52), 0.939 
Dose decreased or 
discontinued  
2.12 (1.49 – 3.02), <0.001 1.97 (1.40 – 2.75), <0.001 1.68 (1.17 – 2.42), 0.005 
Subject taking neither currently 
nor at randomization  
2.58 (1.84 – 3.62), <0.001 1.89 (1.35 – 2.62), <0.001 1.85 (1.28 – 2.65), 0.001 
MRA 
No dose change (Reference) HR (CI), p  HR (CI), p HR (CI), p 
Dose increased or initiated 1.21 (0.83 – 1.74), 0.322 1.14 (0.80 – 1.63), 0.472 1.11 (0.76 – 1.61), 0.595 
Dose decreased or 
discontinued  
1.66 (1.11 – 2.49), 0.013 1.57 (1.06 – 2.33), 0.026 1.73 (1.15 – 2.60), 0.008 
Subject taking neither currently 
nor at randomization  
1.31 (0.95 – 1.80), 0.095 1.12 (0.82 – 1.51), 0.479 1.15 (0.82 – 1.61), 0.408 
HR, Hazard Ratio; CI, Confidence Interval 441 
$ Model 1: Corrected for age, sex, logarithm of eGFR, and logarithm of total dose of loop diuretics until day 7 or discharge (IV + oral/2) 442 
* Corrected for PROTECT Risk Engine: age, previous HF hospitalizations, peripheral edema, systolic blood pressure, serum urea, 443 
creatinine, sodium, and albumin concentrations 444 
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Table 3. The association between the magnitude of hyperkalemia (defined as the number of days 446 
hyperkalemia occurred (1 to 7 days)) or patients’ serum potassium concentrations at baseline (on a 447 
continuous scale) and treatment down-titration.  448 
Down-titration Univariable Model 1$ Model 2* 
ACEi/ARB                                             OR (CI), p                                    OR (CI), p                                   OR (CI), p 
Number of days with 
hyperkalemia 1.06 (0.89 – 1.27), 0.517  N.A. N.A. 
Baseline serum 
potassium, per 1 mEq/L 
1.02 (0.78 – 1.33), 0.879 N.A. N.A. 
MRA                                                       OR (CI), p                                    OR (CI), p                                   OR (CI), p 
Number of days with 
hyperkalemia 1.26 (1.09 – 1.47), 0.003 1.23 (1.04 – 1.44), 0.014 1.41 (1.02 – 1.97), 0.040 
Baseline serum 
potassium, per 1 mEq/L 
1.45 (1.10 – 1.91), 0.008 1.35 (1.01 – 1.80), 0.043 1.51 (0.87 – 2.62), 0.139 
$ Model 1: Corrected for heart rate, logarithm of eGFR, history of hyperlipidemia, history of smoking, NYHA-class, treatment 449 
with beta-blockers, and treatment with MRAs (in ACEi/ARB) or treatment with ACEi/ARB (in MRA)  450 
* Model 2: Corrected for age, sex, BMI, logarithm of eGFR, NYHA-class, left ventricular ejection fraction, systolic blood 451 
pressure, history of COPD, history of diabetes mellitus, history of atrial fibrillation, treatment with beta-blockers, treatment 452 
with ACEi/ARB, treatment with Rolofylline, edema & raised jugular venous pressure, intravenous dose of loop diuretics, 453 
serum sodium concentrations, serum BNP concentrations, and serum hemoglobin concentration.   454 
 455 
